Robbins Geller Rudman & Dowd LLP recently announced it is investigating potential violations of U.S. federal securities laws ...

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Travere Therapeutics, Inc. today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast ...

LGND READ THE FULL LGND RESEARCH REPORT In the wake of the December analyst day, Ligand Pharmaceuticals, Inc.’s (NASDAQ:LGND) ...

Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis (FSGS). The indication represents a $2 billion peak sales opportunity in the U ...

The FDA has extended its review of the company's Filspari. This is a setback for the biotech's leading drug candidate. Travere's leading drug candidate is Filspari, which targets a kidney disorder ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for ...

Jan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics’(TVTX.O), opens new tab drug to treat a type of rare ‌kidney disorder, the ...

U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025 “The fourth quarter closed out an exceptional year of commercial execution with ...